Test Report – Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease

Southwest March 1, 2021

Meeting Chair

Mark Pegram, MD

Stanford Women’s Cancer Center, Palo Alto, CA

Test Chair 2

Test Name 2

Test Location 2

Central April 7, 2021

Meeting Chair

Debu Tripathy, MD

MD Anderson Cancer Center, Houston, TX

Region 3 test test date

Faculty Members

Faculty member content goes here.

More Info

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Info

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana


Download the meeting agenda

View Agenda

Sample Report

Start discovering the insights

View Report

Report Snapshot

  • A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained:
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies


  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.